Medpace Holdings, Inc.
MEDP- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- SEC CIK
- 0001668397
In the last 90 days, Medpace Holdings, Inc. insiders filed 0 open-market purchases and 16 sales; 754 institutions reported holding it in 13F filings for Q3 2026, worth $14.3B in total; superinvestors Giverny Capital and Fundsmith hold it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 23, 2026, 1:09 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 9, 2026 | Feb 10, 2025 | Feb 12, 2024 | Feb 13, 2023 | Feb 14, 2022 |
| Revenue | $2.53B | $2.11B | $1.89B | $1.46B | $1.14B |
| Selling, general and administrative | $197.6M | $180.2M | $161.4M | $131.4M | $108.4M |
| Operating income | $534.9M | $446.9M | $336.8M | $278.7M | $198.6M |
| Income tax | $91.3M | $71.5M | $52.9M | $37.5M | $20.0M |
| Net income | $451.1M | $404.4M | $282.8M | $245.4M | $181.8M |
| EPS, basic | $15.64 | $13.06 | $9.20 | $7.57 | $5.06 |
| EPS, diluted | $15.28 | $12.63 | $8.88 | $7.28 | $4.81 |
| Weighted shares, basic | 28.8M | 31.0M | 30.7M | 32.4M | 35.9M |
| Weighted shares, diluted | 29.5M | 32.0M | 31.8M | 33.7M | 37.7M |
| Margins and growth | |||||
| Operating margin | 21.1% | 21.2% | 17.9% | 19.1% | 17.4% |
| Net margin | 17.8% | 19.2% | 15.0% | 16.8% | 15.9% |
| Revenue growth, year over year | +20.0% | +11.8% | +29.2% | +27.8% | +23.4% |
| Net income growth, year over year | +11.6% | +43.0% | +15.3% | +34.9% | +25.1% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 9, 2026 | Feb 10, 2025 | Feb 12, 2024 | Feb 13, 2023 | Feb 14, 2022 |
| Cash and equivalents | $497.0M | $669.4M | $245.4M | $28.3M | $461.3M |
| Accounts receivable | $402.1M | $296.4M | $298.4M | $253.4M | $186.4M |
| Total current assets | $989.6M | $1.03B | $593.8M | $334.0M | $690.9M |
| Property, plant and equipment | $131.1M | $123.6M | $120.6M | $109.8M | $93.2M |
| Goodwill | $662.4M | $662.4M | $662.4M | $662.4M | $662.4M |
| Intangible assets | $33.4M | $34.4M | $35.8M | $38.0M | $41.4M |
| Total assets | $1.98B | $2.10B | $1.66B | $1.35B | $1.66B |
| Accounts payable | $28.1M | $32.5M | $31.9M | $33.1M | $25.7M |
| Short-term debt | – | – | $0 | $50.0M | – |
| Total current liabilities | $1.34B | $1.10B | $925.1M | $803.5M | $557.2M |
| Total liabilities | $1.52B | $1.28B | $1.10B | $966.1M | $707.0M |
| Shareholders' equity | $459.1M | $825.5M | $559.0M | $386.4M | $952.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 9, 2026 | Feb 10, 2025 | Feb 12, 2024 | Feb 13, 2023 | Feb 14, 2022 |
| Operating cash flow | $713.2M | $608.8M | $433.4M | $388.1M | $263.3M |
| Capital expenditures | $31.4M | $36.5M | $36.6M | $36.9M | $28.3M |
| Free cash flow | $681.9M | $572.3M | $396.7M | $351.2M | $235.1M |
| Stock-based compensation | $34.8M | $25.5M | $20.5M | $21.4M | $14.5M |
| Share buybacks | $917.4M | $169.9M | $144.0M | $847.8M | $62.1M |
| Investing cash flow | -$31.1M | -$28.3M | -$34.6M | -$38.7M | -$31.4M |
| Financing cash flow | -$860.4M | -$154.0M | -$182.6M | -$775.8M | -$44.5M |
| Net change in cash | -$172.4M | $424.0M | $217.2M | -$433.0M | $183.5M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 1.4% | 1.2% | 1.1% | 1.5% | 1.3% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 16, 2026 | 28.0M | −0.7% | SEC |
| Jul 17, 2026 | 27.9M | −0.6% | SEC |
| Apr 17, 2026 | 28.6M | −0.6% | SEC |
| Feb 6, 2026 | 28.4M | −6.8% | SEC |
| Oct 17, 2025 | 28.2M | −9.4% | SEC |
| Jul 18, 2025 | 28.1M | −9.4% | SEC |
| Apr 18, 2025 | 28.7M | −7.2% | SEC |
| Feb 7, 2025 | 30.5M | −1.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.